178 related articles for article (PubMed ID: 27013579)
1. Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein.
Ortega JF; de Conti A; Tryndyak V; Furtado KS; Heidor R; Horst MA; Fernandes LH; Tavares PE; Pogribna M; Shpyleva S; Beland FA; Pogribny IP; Moreno FS
Oncotarget; 2016 Apr; 7(17):24339-47. PubMed ID: 27013579
[TBL] [Abstract][Full Text] [Related]
2. The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway.
de Conti A; Tryndyak V; Koturbash I; Heidor R; Kuroiwa-Trzmielina J; Ong TP; Beland FA; Moreno FS; Pogribny IP
Carcinogenesis; 2013 Aug; 34(8):1900-6. PubMed ID: 23568954
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic responses provide a new mechanistic basis for the chemopreventive effects of folic acid and tributyrin in rat liver carcinogenesis.
Guariento AH; Furtado KS; de Conti A; Campos A; Purgatto E; Carrilho J; Shinohara EM; Tryndyak V; Han T; Fuscoe JC; Ross SA; Beland FA; Pogribny IP; Moreno FS
Int J Cancer; 2014 Jul; 135(1):7-18. PubMed ID: 24302446
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic effects of the chemopreventive agent tributyrin, a butyric acid prodrug, during the promotion phase of hepatocarcinogenesis.
Andrade FO; Furtado KS; Heidor R; Sandri S; Hebeda CB; Miranda MLP; Fernandes LHG; Yamamoto RC; Horst MA; Farsky SHP; Moreno FS
Carcinogenesis; 2019 Aug; 40(8):979-988. PubMed ID: 30590392
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy.
Ohkoshi S; Yano M; Matsuda Y
World J Gastroenterol; 2015 Nov; 21(42):12150-6. PubMed ID: 26576099
[TBL] [Abstract][Full Text] [Related]
6. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
[TBL] [Abstract][Full Text] [Related]
7. Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
von Fallois M; Kosyna FK; Mandl M; Landesman Y; Dunst J; Depping R
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2025-2033. PubMed ID: 33856525
[TBL] [Abstract][Full Text] [Related]
8. The chemopreventive activity of butyrate-containing structured lipids in experimental rat hepatocarcinogenesis.
Heidor R; de Conti A; Ortega JF; Furtado KS; Silva RC; Tavares PE; Purgatto E; Ract JN; de Paiva SA; Gioielli LA; Pogribny IP; Moreno FS
Mol Nutr Food Res; 2016 Feb; 60(2):420-9. PubMed ID: 26548572
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways.
Pathria G; Wagner C; Wagner SN
J Invest Dermatol; 2012 Dec; 132(12):2780-90. PubMed ID: 22832492
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug.
Kuroiwa-Trzmielina J; de Conti A; Scolastici C; Pereira D; Horst MA; Purgatto E; Ong TP; Moreno FS
Int J Cancer; 2009 Jun; 124(11):2520-7. PubMed ID: 19195022
[TBL] [Abstract][Full Text] [Related]
11. Elevated expression of the nuclear export protein, Crm1 (exportin 1), associates with human oesophageal squamous cell carcinoma.
van der Watt PJ; Zemanay W; Govender D; Hendricks DT; Parker MI; Leaner VD
Oncol Rep; 2014 Aug; 32(2):730-8. PubMed ID: 24898882
[TBL] [Abstract][Full Text] [Related]
12. p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1.
Santiago A; Li D; Zhao LY; Godsey A; Liao D
Mol Biol Cell; 2013 Sep; 24(17):2739-52. PubMed ID: 23825024
[TBL] [Abstract][Full Text] [Related]
13. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin JR; Kendra K; Lesinski GB
PLoS One; 2014; 9(7):e102983. PubMed ID: 25057921
[TBL] [Abstract][Full Text] [Related]
14. The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage.
van der Watt PJ; Leaner VD
Biochim Biophys Acta; 2011 Jul; 1809(7):316-26. PubMed ID: 21683812
[TBL] [Abstract][Full Text] [Related]
15. Leptomycin B alters the subcellular distribution of CRM1 (Exportin 1).
Rahmani K; Dean DA
Biochem Biophys Res Commun; 2017 Jun; 488(2):253-258. PubMed ID: 28412356
[TBL] [Abstract][Full Text] [Related]
16. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma.
Li H; Liu Y; Jiang W; Xue J; Cheng Y; Wang J; Yang R; Zhang X
BMC Cancer; 2021 Mar; 21(1):318. PubMed ID: 33765973
[TBL] [Abstract][Full Text] [Related]
17. Methylated chrysin induces co-ordinated attenuation of the canonical Wnt and NF-kB signaling pathway and upregulates apoptotic gene expression in the early hepatocarcinogenesis rat model.
Khan MS; Halagowder D; Devaraj SN
Chem Biol Interact; 2011 Aug; 193(1):12-21. PubMed ID: 21554863
[TBL] [Abstract][Full Text] [Related]
18. Subcellular Distribution of p53 by the p53-Responsive lncRNA
Mitra S; Muralidharan SV; Di Marco M; Juvvuna PK; Kosalai ST; Reischl S; Jachimowicz D; Subhash S; Raimondi I; Kurian L; Huarte M; Kogner P; Fischer M; Johnsen JI; Mondal T; Kanduri C
Cancer Res; 2021 Mar; 81(6):1457-1471. PubMed ID: 33372039
[TBL] [Abstract][Full Text] [Related]
19. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
[TBL] [Abstract][Full Text] [Related]
20. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
